Soluble MHC Compounds with Dynamic Anchors for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Activating T cells to recognize tumor antigens is challenging due to immune tolerance mechanisms, limiting their effectiveness in cancer and infection treatments.
Innovation Solution
Development of compounds comprising a target antigen, a soluble Major Histocompatibility Complex (MHC) molecule, and a dynamic anchor that binds to phosphatidylserine, facilitating programmed self-assembly of peptide-MHC on T cell membranes, enhancing T cell activation by stabilizing TCR-pMHC interactions and bypassing costimulation requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccination methods are used to activate T cells, then the immune response can be stimulated, but the activation of tumor-specific T cells remains insufficient due to immune tolerance mechanisms
Solution Approach 1:
The compound is segmented into three functional modules: antigen portion (for T cell recognition), soluble MHC molecule portion (for stable presentation), and dynamic anchor portion (for membrane attachment). This segmentation allows each component to perform its specific function optimally while working together to overcome immune tolerance and enhance T cell activation reliability
Solution Approach 2:
The invention creates a composite molecular structure combining antigen, soluble MHC, and dynamic anchor into a single compound. This composite structure integrates antigen presentation capability with stable membrane association, enabling robust T cell activation that overcomes the limiting factor of immune tolerance
2Reliability
If antigen alone is used for T cell activation, then the structure is simple, but the activation strength is insufficient
Solution Approach 1:
The compound is divided into three functional modules: antigen portion (for T cell recognition), soluble MHC molecule portion (for stable presentation), and dynamic anchor portion (for membrane attachment). This segmentation allows each component to perform its specific function optimally while working together to achieve strong T cell activation
Solution Approach 2:
The compound performs multiple functions simultaneously: it presents antigen to T cells, stabilizes the antigen-MHC complex on the cell membrane, and anchors the complex to the membrane through phosphatidylserine binding. This multi-functionality achieves strong activation without requiring multiple separate components
3Reliability
If stable pMHC-TCR interactions are to be achieved, then T cell activation is enhanced, but the requirement for costimulation must be bypassed
Solution Approach 1:
The dynamic anchor portion is designed to pre-bind to phosphatidylserine on the T cell membrane before antigen recognition occurs. This preliminary anchoring stabilizes the compound at the membrane, ensuring that when the antigen is recognized by the TCR, the interaction is immediately stable and sustained, effectively bypassing the need for subsequent costimulation signals
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds significantly augment T cell activation by several orders of magnitude, overcoming immune tolerance and enhancing immune responses to tumor or microbial antigens, thereby improving cancer and infection therapies.
Implementation Method 1
a dynamic anchor, which binds to the surface of a T cell
Implementation Method 2
This anchor, in turn, exerts a mechanical force that stabilizes interactions at the TCR-pMHC interface
Implementation Method 3
the compounds described herein utilize positive feedback-driven, programmed self-assembly of peptide-MHC (pMHC) directly on the membrane of T cells
Data Source
AI summary
The disclosure features compounds comprising an antigen portion, a soluble Major Histocompatibility Complex (MHC) molecule portion (e.g., all or an antigen-binding portion of a soluble MHC class I molecule), and a dynamic anchor portion (e.g., an agent, such as Annexin V, that binds to phosphatidylserine). The featured compounds are useful for a variety of therapeutic applications, including, e.g., enhancing a T cell response to an antigen of interest or enhancing a T cell-driven immune response by a subject to an antigen of interest (e.g., a cancer antigen or a microbial antigen).